Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Validation of the four-miRNA biomarker panel MiCaP for prediction of long-term prostate cancer outcome

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

Strand, S. H., Schmidt, L., Weiss, S., Borre, M., Kristensen, H., Rasmussen, A. K. I., ... Sørensen, K. D. (2020). Validation of the four-miRNA biomarker panel MiCaP for prediction of long-term prostate cancer outcome. Scientific Reports, 10. https://doi.org/10.1038/s41598-020-67320-y

CBE

MLA

Vancouver

Author

Strand, Siri H ; Schmidt, Linnéa ; Weiss, Simone ; Borre, Michael ; Kristensen, Helle ; Rasmussen, Anne Karin Ildor ; Daugaard, Tina Fuglsang ; Kristensen, Gitte ; Stroomberg, Hein Vincent ; Røder, Martin Andreas ; Brasso, Klaus ; Mouritzen, Peter ; Sørensen, Karina Dalsgaard. / Validation of the four-miRNA biomarker panel MiCaP for prediction of long-term prostate cancer outcome. I: Scientific Reports. 2020 ; Bind 10.

Bibtex

@article{6b5002eac3de4f6a8af1cb52fdd1ed6d,
title = "Validation of the four-miRNA biomarker panel MiCaP for prediction of long-term prostate cancer outcome",
abstract = "Improved prostate cancer prognostic biomarkers are urgently needed. We previously identified the four-miRNA prognostic biomarker panel MiCaP ((miR-23a-3p × miR-10b-5p)/(miR-133a-3p × miR-374b-5p)) for prediction of biochemical recurrence (BCR) after radical prostatectomy (RP). Here, we identified an optimal numerical cut-off for MiCaP dichotomisation using a training cohort of 475 RP patients and tested this in an independent cohort of 281 RP patients (PCA281). Kaplan-Meier, uni- and multivariate Cox regression analyses were conducted for multiple endpoints: BCR, metastatic-(mPC) and castration-resistant prostate cancer (CRPC), prostate cancer-specific (PCSS) and overall survival (OS). Functional effects of the four MiCaP miRNAs were assessed by overexpression and inhibition experiments in prostate cancer cell lines. We found the numerical value 5.709 optimal for MiCaP dichotomisation. This was independently validated in PCA281, where a high MiCaP score significantly [and independent of the Cancer of the Prostate Risk Assessment Postsurgical (CAPRA-S) score] predicted BCR, progression to mPC and CRPC, and PCSS, but not OS. Harrell's C-index increased upon addition of MiCaP to CAPRA-S for all endpoints. Inhibition of miR-23a-3p and miR-10b-5p, and overexpression of miR-133a-3p and miR-374b-5p significantly reduced cell survival. Our results may promote future implementation of a MiCaP-based test for improved prostate cancer risk stratification.",
author = "Strand, {Siri H} and Linn{\'e}a Schmidt and Simone Weiss and Michael Borre and Helle Kristensen and Rasmussen, {Anne Karin Ildor} and Daugaard, {Tina Fuglsang} and Gitte Kristensen and Stroomberg, {Hein Vincent} and R{\o}der, {Martin Andreas} and Klaus Brasso and Peter Mouritzen and S{\o}rensen, {Karina Dalsgaard}",
year = "2020",
month = "7",
day = "1",
doi = "10.1038/s41598-020-67320-y",
language = "English",
volume = "10",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

RIS

TY - JOUR

T1 - Validation of the four-miRNA biomarker panel MiCaP for prediction of long-term prostate cancer outcome

AU - Strand, Siri H

AU - Schmidt, Linnéa

AU - Weiss, Simone

AU - Borre, Michael

AU - Kristensen, Helle

AU - Rasmussen, Anne Karin Ildor

AU - Daugaard, Tina Fuglsang

AU - Kristensen, Gitte

AU - Stroomberg, Hein Vincent

AU - Røder, Martin Andreas

AU - Brasso, Klaus

AU - Mouritzen, Peter

AU - Sørensen, Karina Dalsgaard

PY - 2020/7/1

Y1 - 2020/7/1

N2 - Improved prostate cancer prognostic biomarkers are urgently needed. We previously identified the four-miRNA prognostic biomarker panel MiCaP ((miR-23a-3p × miR-10b-5p)/(miR-133a-3p × miR-374b-5p)) for prediction of biochemical recurrence (BCR) after radical prostatectomy (RP). Here, we identified an optimal numerical cut-off for MiCaP dichotomisation using a training cohort of 475 RP patients and tested this in an independent cohort of 281 RP patients (PCA281). Kaplan-Meier, uni- and multivariate Cox regression analyses were conducted for multiple endpoints: BCR, metastatic-(mPC) and castration-resistant prostate cancer (CRPC), prostate cancer-specific (PCSS) and overall survival (OS). Functional effects of the four MiCaP miRNAs were assessed by overexpression and inhibition experiments in prostate cancer cell lines. We found the numerical value 5.709 optimal for MiCaP dichotomisation. This was independently validated in PCA281, where a high MiCaP score significantly [and independent of the Cancer of the Prostate Risk Assessment Postsurgical (CAPRA-S) score] predicted BCR, progression to mPC and CRPC, and PCSS, but not OS. Harrell's C-index increased upon addition of MiCaP to CAPRA-S for all endpoints. Inhibition of miR-23a-3p and miR-10b-5p, and overexpression of miR-133a-3p and miR-374b-5p significantly reduced cell survival. Our results may promote future implementation of a MiCaP-based test for improved prostate cancer risk stratification.

AB - Improved prostate cancer prognostic biomarkers are urgently needed. We previously identified the four-miRNA prognostic biomarker panel MiCaP ((miR-23a-3p × miR-10b-5p)/(miR-133a-3p × miR-374b-5p)) for prediction of biochemical recurrence (BCR) after radical prostatectomy (RP). Here, we identified an optimal numerical cut-off for MiCaP dichotomisation using a training cohort of 475 RP patients and tested this in an independent cohort of 281 RP patients (PCA281). Kaplan-Meier, uni- and multivariate Cox regression analyses were conducted for multiple endpoints: BCR, metastatic-(mPC) and castration-resistant prostate cancer (CRPC), prostate cancer-specific (PCSS) and overall survival (OS). Functional effects of the four MiCaP miRNAs were assessed by overexpression and inhibition experiments in prostate cancer cell lines. We found the numerical value 5.709 optimal for MiCaP dichotomisation. This was independently validated in PCA281, where a high MiCaP score significantly [and independent of the Cancer of the Prostate Risk Assessment Postsurgical (CAPRA-S) score] predicted BCR, progression to mPC and CRPC, and PCSS, but not OS. Harrell's C-index increased upon addition of MiCaP to CAPRA-S for all endpoints. Inhibition of miR-23a-3p and miR-10b-5p, and overexpression of miR-133a-3p and miR-374b-5p significantly reduced cell survival. Our results may promote future implementation of a MiCaP-based test for improved prostate cancer risk stratification.

U2 - 10.1038/s41598-020-67320-y

DO - 10.1038/s41598-020-67320-y

M3 - Journal article

VL - 10

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

ER -

ID: 60879569